A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants
PHASE1CompletedINTERVENTIONAL
Enrollment
53
Participants
Timeline
Start Date
February 20, 2023
Primary Completion Date
January 18, 2024
Study Completion Date
January 18, 2024
Conditions
Healthy Volunteers
Interventions
DRUG
E2086
E2086 tablets.
DRUG
Placebo
E2086 matched placebo tablets.
Trial Locations (1)
78217
Worldwide Clinical Trials, San Antonio
All Listed Sponsors
lead
Eisai Inc.
INDUSTRY
NCT05745207 - A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants | Biotech Hunter | Biotech Hunter